In this issue:
Patient perspectives on health-related transportation access
Does daratumumab induction impact stem cell mobilisation?
Front-line daratumumab-based regimens more efficacious, but also more toxic
Immune profile aids identification of early relapse after MRD resurgence
Deficits in quality of PROs in myeloma trials
PROs with belantamab mafodotin-based triplet from DREAMM-8
Real-world effectiveness and safety of talquetamab
Teclistamab active in patients exposed to other BCMA-targeted therapy
A BCMA-mRNA vaccine is a promising therapeutic for multiple myeloma
PT-112 demonstrates safety and activity in multi-refractory disease
Please login below to download this issue (PDF)